Role of IL-17B in cancer reviewed in Frontiers in Immunology
PRESS RELEASE – 1st patient treated & 10-y anniversary
10 March 2020Jeremy Bastid nominated as Chief Executive Officer
1 July 2020
We review the current understanding on the IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies.
The emerging role of the IL-17B/IL-17RB pathway in cancer, published in Frontiers in Immunology and co-authoring Jeremy Bastid, Cécile Dejou, Aurélie Docquier and Nathalie Bonnefoy (OREGA Biotech).
The review article is accessible here.
